Global Benign Prostatic Hyperplasia (BPH) And Prostate Treatment Market Report By Treatment Type (BPH Drugs (Alpha Blockers, 5-Apiha Reductase Inhibitors, Phosphodiesterase-5 (PDF-5) Inhibitors, Muscarinic Receptor Antagonist (MRA), Combination Drug), BPH Devices (Prostatic Stents, Suture Base Implant Systems, Transurethral RF Thermal Therapy Devices)), By Distribution Channel (Institutional Sales (Hospitals, Ambulatory Surgical Centres, Specialty Clinics), Retail Sales (Retail Pharmacies, Drug Stores), Online Pharmacies) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2023-2032

Global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment Market Overview

Benign prostatic hyperplasia (BPH) is the medical condition typically observed in old-aged men characterized by enlargement of the prostate gland resulting in squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney, and urinary tract. It is often treated with prescribed doses of alpha-blockers, 5-alpha reductase, or a combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed. The number of men seeking treatment for benign prostatic hyperplasia (BPH) is expected to rise in the coming years due to the growing aging male population and the increasing prevalence of obesity, cardiovascular diseases, and erectile dysfunction. BPH is a common condition in aging men and the most common cause of lower urinary tract symptoms. The prevalence of BPH rises after 40 years, with a prevalence of 8% to 60% at age 90 years. As per United Nations, the number of older persons is growing faster than the younger age groups. The global population aged over 80 years is projected to triple, increasing from 137 million in 2017 to 425 million in 2050. Obesity affects the geriatric population in parallel to that of the general population.  The prevalence of obesity in the older population has been rising and now poses a major global threat in developed and developing countries. All of these will contribute to the growing prevalence of BPH, thus therapeutics.
 

The rise in awareness regarding urological diseases contributes to the growth of the benign prostatic hyperplasia treatment market. The growing preference for advanced treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), and other minimally invasive techniques are also projected to foster the market growth during the timespan. Even if BPH is treated with drugs and surgeries, it does come with some side effects. Common side effects include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Surgeries' side effects include pain, problems urinating, and other infections. This may hinder the market growth.

The global benign prostatic hyperplasia treatment market is highly fragmented. Pfizer Inc., NxThera Inc., NeoTract Inc., Sanofi S.A, GlaxoSmithKline Pic, Allergan Pic., Teva Pharmaceutical industries Ltd., Mylan N.V., Eli Lily & Company, Cardinal Health Inc. are key players associated with the market. Key companies are adopting merger & acquisition strategies and joint ventures to gain a more significant share in the overall market. Several companies are spending in R&D for the exploration of better treatment.

In this research report, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market is segmented by therapy and region.
 
Analysis, By Treatment Type:
By treatment type, the global benign prostatic hyperplasia therapeutics market is segmented into drugs and surgeries. The drug segment occupies a major share in 2022. Drugs alone are known to be more effective. Drug therapy is growing due to its high effectiveness, superior symptomatic benefit, and significant reduction in adverse events. 

Analysis, By Distribution Channel:
Among surgical treatments, Transurethral Resection of the Prostate holds the maximum share for the year 2022.
 
Analysis, By Region
Geographically, the global benign prostatic hyperplasia treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a dominant region in the global market, while the Asia-Pacific region is anticipated to grow faster during the forecast period. North America is expected to grow with the rising prevalence of benign prostatic hyperplasia, greater access to treatment. Also, the region is home to many market players and is blessed with skilled expertise. Asia Pacific growth is driven by factors including a high male population base, increased disposable income, and enhanced patient awareness about benign prostatic hyperplasia.
 
Market Segmentation covered in the Report:

By Treatment Type

• BPH Drugs (Alpha Blockers, 5-Apiha Reductase Inhibitors, Phosphodiesterase-5 (PDF-5) Inhibitors, Muscarinic Receptor Antagonist (MRA), Combination Drug)
• BPH Devices (Prostatic Stents, Suture Base Implant Systems, Transurethral RF Thermal Therapy Devices)

By Distribution Channel

• Institutional Sales (Hospitals, Ambulatory Surgical Centres, Specialty Clinics)
• Retail Sales (Retail Pharmacies, Drug Stores)
• Online Pharmacies

 
By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa